



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



SZM-1209

Item No. 38494

CAS Registry No.: 2919801-86-6
Formal Name: N-[5-[[2-[[[4-[(ethylsulfonyl)amino]cyclohexyl]carbonyl]amino]-5-fluoro-6-benzothiazolyl]oxy]-2-fluorophenyl]-3-(trifluoromethyl)benzeneacetamide

MF: C₃₁H₂₉F₅N₄O₅S₂
FW: 696.7


Purity: ≥98%

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

SZM-1209 is supplied as a crystalline solid. A stock solution may be made by dissolving the SZM-1209 in the solvent of choice, which should be purged with an inert gas. SZM-1209 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of SZM-1209 in these solvents is approximately 10 and 15 mg/ml, respectively.

Description

SZM-1209 is an inhibitor of receptor-interacting serine/threonine kinase 1 (RIPK1).¹ It selectively binds to RIPK1 over RIPK3 (K_d s = 85 and >10,000 nM, respectively) and inhibits necrosome formation and phosphorylation of RIPK1 induced by TNF- α , SM-164 (Item No. 28632), and Z-VAD-FMK in HT-29 cells (EC_{50} = 22.4 nM). SMZ-1209 (10 and 20 mg/kg) decreases reductions in body temperature and improves survival in a mouse model of systemic inflammatory response syndrome (SIRS) induced by TNF- α and Z-VAD-FMK. It also reduces lung RIPK1 phosphorylation, IL-6 and TNF- α levels, and total protein content, as well as decreases the number of hemorrhagic sites and congestion edema, in a mouse model of acute lung injury (ALI) induced by short-term intratracheal exposure to 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK; Item No. 16414).

Reference

1. Zhang, X., Han, Q., Hou, R., *et al.* Targeting receptor-interacting protein kinase 1 by novel benzothiazole derivatives: Treatment of acute lung injury through the necroptosis pathway. *J. Med. Chem.* **66(7)**, 5261-5278 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/14/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM